P311 Antibody - #DF14359

Fig. 1: NREP is upregulated and predicts poor prognosis value in BC patients. A Venn diagram of 22 upregulated differentially expressed genes (DEGs) in nine BC databases from GEO. B Heat map of 22 DEGs in nine BC databases. C Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of 22 DEGs was analyzed by DAVIVD. D Gene ontology (GO) enrichment analysis of 22 DEGs was analyzed by DAVIVD. BP biological process, CC cellular component, MF molecular function. E The mRNA expression level of NREP in nine BC databases. T: tumor tissues; C: normal tissues. F The expression of NREP in the tumor, para-carcinoma, and healthy tissues of BC patients (analyzed by Breast Cancer Gene-Expression Miner v4.9). G Survival curves of BC patients with high or low NREP level (analyzed by Biomedical Informatics Institute). Overall survival (OS), metastasis-free survival (MFS), progression-free interval (PFI), and progression-free survival (PFS). H IHC staining of BC clinical samples with low or high NREP expression. Data were expressed as mean ± SD. *P 

Fig. 2: NREP is transcriptional activated by HIF-1α. A The expression of NREP in hypoxia and normoxia BC cells (data from GSE3188 and GSE111259). B The expression of NREP in HIF-1α depleted BC cells (data from GSE3188). C The mRNA expression of NREP in different BC cell lines (SK-BR-3, MCF-7, MDA-MB-468, MDA-MB-231) at normoxia or hypoxia was measured by qPCR. The mRNA expression of HIF-1α (D) and NREP (E) in HIF-1α inhibited MDA-MB-468 or MDA-MB-231 cells were measured by qPCR. F The protein expression and quantification data of NREP and HIF-1α in MDA-MB-468 or MDA-MB-231 cells were measured by western blot. G, H Luciferase reporter assay was used to confirm the binding sites of HIF-1α on NREP promoter. I, J ChIP-PCR assay was used to confirm that HIF-1α could directly bind with the promoter of NREP. Data were expressed as mean ± SD. *P